# Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

> **NCT07630649** · PHASE2 · RECRUITING · sponsor: **Adverum Biotechnologies, Inc.** · enrollment: 15 (estimated)

## Conditions studied

- Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD

## Interventions

- **GENETIC:** Ixo-vec

## Key facts

- **NCT ID:** NCT07630649
- **Lead sponsor:** Adverum Biotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-02
- **Primary completion:** 2031-06
- **Final completion:** 2031-06
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07630649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07630649, "Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07630649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*